Research programme: TGR5 agonists - Enveda Biosciences
Alternative Names: GPBAR1 agonists - Enveda Biosciences; Takeda G protein-coupled receptor 5 - Enveda BiosciencesLatest Information Update: 03 Feb 2023
At a glance
- Originator Enveda Biosciences
- Class Anti-inflammatories; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 26 Dec 2022 Research programme: TGR5 agonists - Enveda Biosciences is available for licensing as of 26 Dec 2022. https://www.envedabio.com/what-we-do
- 26 Dec 2022 Preclinical trials in Inflammation in USA (unspecified route), prior to December 2022 (Enveda Bioscience pipeline, December 2022)